Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Diabetes and Endo
    • Dasotraline...

    Dasotraline significantly reduces binge eating related obsessive compulsive behaviour: Study

    Written by Dr. Kamal Kant Kohli Kohli Published On 2019-10-10T20:28:08+05:30  |  Updated On 14 Oct 2021 11:50 AM IST
    Dasotraline significantly reduces binge eating related obsessive compulsive behaviour: Study

    Treatment with a norepinephrine-dopamine reuptake inhibitor (NDRI), dasotraline in patients with binge eating disorder (BED) helped to reduce body weight, according to study results presented at the Psych Congress 2019. The findings were presented by Leslie Citrome, New York Medical College in Valhalla.


    Another secondary analysis led by Citrome presented another secondary analysis at Psych Congress 2019, showing that dasotraline significantly reduced binge-related obsessional thoughts and compulsive behaviours.


    Mayo Clinic defines binge-eating disorder as a serious eating disorder in which a person frequently consumes unusually large amounts of food and feel unable to stop eating.


    In July 2019, Sunovion announced the FDA acceptance of their New Drug Application for dasotraline seeking the indication for moderate-to-severe binge eating disorder, with an action date of May 14, 2020.


    The study included 155 participants randomized to receive a flexible, once-daily dose of 4, 6, or 8 mg of dasotraline. They were compared with 160 individuals on placebo. The average daily dose of dasotraline was 5.5 mg/day.


    DSM-5 criteria was defined as at least two or more binge-eating days per week for a minimum of 6 months, or 3-plus binge-eating days per week during the past 2 weeks before randomization.


    All participants (ages 18-55) were diagnosed with at least moderate binge-eating disorder according to DSM-5 criteria. The vast majority of the participants were white females, with an average of 4.3 binge-eating days per week and 5.6 binge-eating episodes per week.


    Over 75% of the cohort had obesity at the start of the study, evenly distributed between obesity class I (24.9% BMI 30 to <35), II (29.3% BMI 35 to <40), and III (21.8% BMI ≥40). Around 18% of the cohort were considered overweight, with a BMI from 25 to <30, but <6% of the cohort had a BMI <25.


    Key findings of the study include:




    • After 12 weeks, the once-daily investigational long-acting dopamine/norepinephrine reuptake inhibitor was associated with a significant 12.57 lbs (5.7 kg) reduction in body weight reduction compared with a 0.88 lb (0.4 kg) gain in placebo.

    • Study participants on dasotraline also saw a 2-point reduction in BMI versus a 0.2 increase among those on placebo.

    • Far more participants on dasotraline achieved a "clinically meaningful" reduction in weight (≥5%) than those on placebo did (45.3% vs 4.1%).

    • Nearly 14% of patients on dasotraline were also able to achieve a weight reduction of ≥10%, while no patients on placebo were able to.

    • When broken down by weight class, those who began dasotraline with obesity (classes 1-3) saw the greatest magnitude of weight reduction over the course of 12 weeks:

      • Obesity: -13.67 lbs (-6.2 kg)

      • Overweight: -12.79 lbs (-5.8 kg)

      • Normal weight: -10.14 lbs (-4.6 kg)




    Another secondary analysis led by Citrome showed that:




    • Measured on the Yale-Brown Obsessive-Compulsive scale Modified for Binge Eating (YBOCS-BE), dasotraline participants had a significant change in total score (effect size=0.96), obsessions subscale score (effect size=0.95), and compulsions subscale score (effect size =0.87) compared with placebo. Improvements in all these scales were significant after only 2 weeks of treatment.

    • Compared with placebo, significant improvements were seen in several types of obsessional thoughts and compulsive behaviors measured for in the questionnaire subscales:

      • Degree of control over thoughts to binge eat

      • Resistance to thoughts to binge eat

      • Distress associated with thoughts to binge eat

      • Interference due to thoughts to binge eat

      • Time occupied by obsessive thoughts to binge eat



    • Patients on dasotraline also saw a significant improvement in symptoms, as rated by the Binge Eating Clinical Global Impression-Severity (CGI-S) score.

    • Among these patients an endpoint CGI-Severity score of 1 (normal) was achieved by 52.3% of patients and was associated with a mean endpoint YBOCS-BE score of 0.5, indicating remission of binge-related obsessions and compulsions in the majority of patients.


    Taken together, these secondary analyses of dasotraline found the medication to be associated with meaningful reductions in binge eating days per week, weight, and BED-related compulsions and obsessions after 12 weeks of treatment.


    References:

    Citrome L, et al "Effect of dasotraline on body weight in patients with binge-eating disorders" Psych Congress 2019; Poster 143.




    Citrome L, et al "Dasotraline for treatment of adults with binge-eating disorder: effect on binge-related obsessions and compulsions" Psych Congress 2019; Poster 240.



    binge eatBinge Eating DisorderBMIcompulsive behavioursdasotralineeating disorderLeslie CitromeMedical newsobsessional thoughtsPsych Congress 2019recent medical newsweight lossweight reduction
    Source : With inputs from Psych Congress 2019

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok